NeoGenomics (NEO) said Wednesday it expects 2025 total revenues in the range of $735 million to $745 million.
Analysts surveyed by FactSet expect $727.8 million.
NeoGenomics said, as part of its long-range financial plan, it intends to achieve 12-13% revenue growth annually and positive cash flow from operations in 2025 and beyond. The company also aims to serve over 1 million patients per year by 2028.
NeoGenomics shares were up almost 4% in recent premarket activity.